Disposition of 1500 shares by Reardon Andrew of Ligand Pharmaceuticals at 106.3937 subject to Rule 16b-3

Read at macroaxis.com

Published over two months ago View all stories for Quantex Fund | Quantex Fund Hype Analysis

Disposition of 1500 common stock at 106.3937 of Ligand Pharmaceuticals by Reardon Andrew on 28th of August 2024. This event was filed by Ligand Pharmaceuticals Incorporated with SEC on 2024-08-28. Statement of changes in beneficial ownership - SEC Form 4

We analyze Quantex Fund's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Quantex Fund using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Quantex Fund based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Quantex Fund mutual fund to make a market-neutral strategy. Peer analysis of Quantex Fund could also be used in its relative valuation, which is a method of valuing Quantex Fund by comparing valuation metrics with similar companies.

Quantex Fund financial ratios help investors to determine whether Quantex Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Quantex with respect to the benefits of owning Quantex Fund security.